**Table S4: Viral Suppression**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Population Code** | **Study Reference** | **Outcome** | **Period (year if known)** | **Estimate (%) (95%CI)**  | **n/N** |
| Burkina Faso 1 | Low *et al*, 2014 [[5](#_ENREF_57)6] | Undetectable PVL (≤300 copies/mm3) | Median of 3.4 years on ART | 48.3 (40.7 - 56.0) \* | 84/174 |
|  | Huet *et al,* 2011 [[39](#_ENREF_19)] &Konate *et al,* 2011 [[3](#_ENREF_41)8] | Undetectable PVL (≤300 copies/mm3) | 6 months after ART initiation  | 79.4 (62.1 - 91.3) c  | 27/34 |
|  |  |  | 12 months after ART initiation  | 77.1 (59.8 - 89.6) c | 27/35 |
|  |  |  | 18 months after ART initiation  | 80.0 (61.4 - 92.3) c | 24/30 |
|  |  |  | 24 months after ART initiation b | 87.5 (47.4 - 99.7) c | 7/8 |
|  |  |  | 30 months after ART initiation b | 75.0 (42.8 - 94.5) c | 9/12 |
|  |  |  | 36 months after ART initiation  | 81.8 (59.7 - 94.8) c | 18/22 |
|  |  | Primary virological success rate (defined as 2 samples ≤300 copies/mm3) | Total follow-up on ART (median 32 months) | 76.7 (61.4 - 88.2) c | 36/47 |
| Dominican Republic 1 | Donastorg *et al*, 2014 [[5](#_ENREF_54)3] a | Undetectable PVL (<50 copies/mm3) | Median of 5 years since HIV diagnosis | 59.6 (52.3 - 66.6) \* | 115/193 |
| Kenya 1 | Graham *et al,* 2010 [28] | Undetectable PVL (≤100 copies/mm3) | 3 months after ART initiation | 40.2 (30.4 - 50.7) | 39/97 |
|  |  |  | 6 months after ART initiation | 72.6 (62.5 - 81.3) \* | 69/95 |
| Vietnam 1 | Dean *et al,* 2011 [[4](#_ENREF_45)3] a | Undetectable PVL (≤180 copies/mm3) | Enrolment (2008 – 2009) | 44.8 (26.5 - 64.3) \* | 13/29 |

FSW – female sex worker, ART – antiretroviral therapy, PVL – plasma viral load
a Data was provided by study authors.
 bOutcome estimate only reported in Huet *et al,* 2011 [[39](#_ENREF_19)].
c 95% confidence interval reported in study.
\* highlights the study estimates used in pooled estimates.